• DOI:10.1101/2021.06.28.21259673
• Corpus ID: 235689169

Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda

@inproceedings{Acevedo2021InfectivityAI,
  title={Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda},
  author={M{\'o}nica L. Acevedo and Luis Antonio Alonso-Palomares and Andr{\'e}s Bustamante and Aldo Gaggero and Fabio Paredes and Claudia P. Cort{\'e}s and Fernando Valiente-Echeverr{\'i}a and Ricardo Soto-Rifo},
  booktitle={medRxiv},
  year={2021}
}

• M. Acevedo, L. Alonso-Palomares, +5 authors R. Soto-Rifo
• Published in medRxiv 1 July 2021
• Biology

Background: The newly described SARS-CoV-2 lineage C.37 was recently classified as a variant of interest by the WHO (Lambda variant) based on its high circulation rates in South American countries and the presence of critical mutations in the spike protein. The impact of such mutations in infectivity and immune escape from neutralizing antibodies are entirely unknown. Methods: We performed a pseudotyped virus neutralization assay and determined the impact of the Lambda variant on infectivity and immune escape using plasma samples from healthcare workers (HCW) from two centers in Santiago, Chile who received the two-doses scheme of the inactivated virus vaccine CoronaVac. Results: We observed an increased infectivity mediated by the Lambda spike protein that was even higher than that of the D614G (lineage B) or the Alpha and Gamma variants. Compared to the Wild type (lineage A), neutralization was decreased by 3.05-fold for the Lambda variant while it was 2.33-fold for the Gamma variant and 2.03-fold for the Alpha variant. Conclusions: Our results indicate that mutations present in the spike protein of the Lambda variant of interest confer increased infectivity and immune escape from neutralizing antibodies elicited by CoronaVac. These data reinforce the idea that massive vaccination campaigns in countries with high SARS-CoV-2 circulation must be accompanied by strict genomic surveillance allowing the identification of new isolates carrying spike mutations and immunology studies aimed to determine the impact of these mutations in immune escape and vaccines breakthrough.